OTLK - Outlook Therapeutics Inc. (OTLK) Q2 2024 Earnings Call Transcript
2024-05-16 14:35:26 ET
Outlook Therapeutics, Inc. (OTLK)
Q2 2024 Earnings Conference Call
May 16, 2024 8:30 AM ET
Company Participants
Jenene Thomas - IR, JTC Team, LLC
Russell Trenary - President & CEO
Lawrence Kenyon - Chief Financial Officer
Conference Call Participants
Julian Harrison - BTIG
Eddie Hickman - Guggenheim Securities
Douglas Tsao - HC Wainwright
Timothy Chiang - Capital One
Kemp Dolliver - Brookline Capital Markets
Ed Woo - Ascendiant Capital Markets
Daniil Gataulin - Chardan
Presentation
Operator
Hello, and welcome to the Outlook Therapeutics Inaugural Quarterly Update Conference Call and Webcast. As a brief reminder all participants are currently in a listen-only mode. [Operator Instructions] Following the presentation, there will be a question-and-answer session. Note that this webcast is being recorded at the company's request and a replay will be made available on the company's website following the end of the event. It is now my pleasure to turn the call over to Jenene Thomas of Investor Relations.
Jenene Thomas
Thank you, Darryl. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the federal securities laws and are based on Outlook Therapeutics current expectations, and actual results could differ materially.
As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the Outlook Therapeutics Annual Report on Form 10-K for the fiscal year ended September 30, 2023 and in other reports filed with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website.
We encourage you to review these documents carefully. Additionally, certain information contained in this webcast release to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own estimates and research. While the company believes that these third-party sources to be reliable, as of the date of this presentation that has not independently verified and makes no representation as to the adequacy, fairness, accuracy or completeness of that or that any independent source has verified any information from third-party sources....
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript